<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rmt</journal-id><journal-title-group><journal-title xml:lang="ru">Общая реаниматология</journal-title><trans-title-group xml:lang="en"><trans-title>General Reanimatology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1813-9779</issn><issn pub-type="epub">2411-7110</issn><publisher><publisher-name>FSBI "SRIGR" RAMS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15360/1813-9779-2013-4-30</article-id><article-id custom-type="elpub" pub-id-type="custom">rmt-121</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФУНДАМЕНТАЛЬНЫЕ ОСНОВЫ АНЕСТЕЗИОЛОГИИ-РЕАНИМАТОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FUNDAMENTALS OF ANESTHESIOLOGY AND REANIMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Влияние пропофола на анестетическое прекондиционирование миокарда севофлураном в эксперименте</article-title><trans-title-group xml:lang="en"><trans-title>Effect of Propofol on Sevoflurane-Induced Myocardial Preconditioning in the Experiment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борисов</surname><given-names>К. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Borisov</surname><given-names>K. Yu</given-names></name></name-alternatives><email xlink:type="simple">archont210@mail.ru</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мороз</surname><given-names>В. В</given-names></name><name name-style="western" xml:lang="en"><surname>Moroz</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гребенчиков</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Grebenchikov</surname><given-names>O. A.</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плотников</surname><given-names>Е. Ю.,</given-names></name><name name-style="western" xml:lang="en"><surname>Plotnikov</surname><given-names>E. Yu,</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левиков</surname><given-names>Д. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Levikov</surname><given-names>D. I.</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черпаков</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherpakov</surname><given-names>R. A.</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лихванцев</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Likhvantsev</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>20</day><month>08</month><year>2013</year></pub-date><volume>9</volume><issue>4</issue><issue-title>Том IX № 4 2013 г.</issue-title><fpage>30</fpage><lpage>30</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Борисов К.Ю., Мороз В.В., Гребенчиков О.А., Плотников Е.Ю., Левиков Д.И., Черпаков Р.А., Лихванцев В.В., 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="ru">Борисов К.Ю., Мороз В.В., Гребенчиков О.А., Плотников Е.Ю., Левиков Д.И., Черпаков Р.А., Лихванцев В.В.</copyright-holder><copyright-holder xml:lang="en">Borisov K.Y., Moroz V.V., Grebenchikov O.A., Plotnikov E.Y., Levikov D.I., Cherpakov R.A., Likhvantsev V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.reanimatology.com/rmt/article/view/121">https://www.reanimatology.com/rmt/article/view/121</self-uri><abstract><p>Цель исследования — оценить выраженность кардиопротекторных свойств севофлурана и пропофола в остром эксперименте на крысах после тотальной ишемии/реперфузии при их раздельном и совместном применении. Материалы и методы. Исследование выполнено на 50 самцах белой беспородной крысы весом 202±19 г (M±ff) с использование модели тотальной ишемии/реперфузии (И/Р). Случайным образом сформировано 5 групп: 1-я — хлоралгидрат 300 мг/кг внутрибрюшинно, ИВЛ 15 минут. 2-я — ингаляционная индукция севофлураном в эксикаторе, ИВЛ, введение севофлурана в дыхательный контур в дозе примерно 2—2,5 МАК на выдохе в течение 15 минут — моделирование анестетического прекондиционирования (АПК). 3-я — анестезия и АПК севофлураном, затем моделировали 10 минутную ишемию с последующей реанимацией и 5-и минутной реперфузией. 4-я — анестезия хлоралгидратом, вводили пропофол 2,5 мг/кг в правую внутреннюю яремную вену, моделировали И/Р. 5-я — анестезия хлоралгидратом, введение пропофола в правую внутреннюю яремную вену, моделирование АПК севофлураном. У всех животных извлекали и гомогенизировали сердца для дальнейшего изучения. Исследовали концентрацию общей и фосфорилированной формы гликогенсинтетазы киназы-3/8 (ГСК-3^ и фосфо-ГСК-3в, соответственно) методом вестерн-блоттинга. Результаты. Концентрация общей ГСК-3/3 в группах была сопоставима. В группе 2 концентрация фосфо-ГСК-3/8 повышалась в 1,5 раза (р&lt;0,05), еще больший прирост (более чем в 2 раза) наблюдался в группе 3 (р&lt;0,05). В группе 4 концентрация фосфо-ГСК-3в повышалась незначительно. В группе 5 концентрация фосфо-ГСК-3/8 снижалась приблизительно 2 раза меньше, чем в группе 1 (р&lt;0,05). Заключение. Можно предположить наличие у севофлурана кардиопротекторных свойств, выражающихся в значительном повышении уровня фосфо-ГСК-3/8. Пропофол не оказывает значимого кардиопротекторного эффекта, а в сочетании с севофлураном, вероятно, полностью лишает последний кардиопротекторных свойств, снижая уровень фосфо-ГСК-3/8 ниже контрольных значений, что может быть связано с антиоксидантными свойствами пропофола. Очевидно, что потребуется дальнейшее продолжение исследования с формированием группы ишемии/реперфузии на фоне сочетанного применения этих анестетиков. Ключевые слова: анестетическое прекондиционирование, севоран, гликогенсинтетаза киназа-3/8, вестерн-блоттинг.</p></abstract><trans-abstract xml:lang="en"><p>Objective: to estimate the magnitude of the cardioprotective properties of sevoflurane and propofol, when they are used alone and in combination in the acute experiment on rats after total ischemia/reperfusion (I/R). Materials and methods. The investigation was conducted on 50 male albino outbred rats weighing 202±19 g (M±ff), by using a total I/R model. The animals were randomized into 5 groups: 1) intraperitoneal chloral hydrate 300 mg/kg; 15-minute mechanical ventilation (MV); 2) inhalation induction with sevoflurane in an exsiccator; MV; injection of about 2—2.5 MAC sevoflurane in the expiratory breathing circuit for 15 minutes — anesthetic preconditioning simulation (APS); 3) anesthesia and APS with sevoflurane; then 10-minute ischemia simulation, followed by resuscitation and 5-minute reperfusion; 4) chloral hydrate anesthesia; injection of propofol 2.5 mg/kg in the right internal jugular vein; APS simulation; 5) chloral hydrate anesthesia; injection of propofol 2.5 mg/kg in the right internal jugular vein; and simulation of APS with sevoflurane. The hearts were extracted from all the animals and homogenized for further examination. The concentrations of total and phosphorylated glycogen synthase kinase-3/8 (GSK-3/8 and pGSK-3/8, respectively) were estimated by Western blotting. Results. The concentration of total GSK-3/8 was comparable in the groups. Group 2 showed a 1.5-fold increase in pGSK-3^ concentrations  (p&lt;0.05), a more increment (by more than twice) was observed in Group 3 (p&lt;0.05). The concentration of pGSK-30 rose slightly in Group 4. In Group 5, the level of pGSK-30 decreased approximately twice that in Group 1 (p&lt;0.05). Conclusion. Sevoflurane can be expected to have cardioprotective properties manifested as a considerably elevated p-GSK-Эв level. Propofol fails to exert a significant cardioprotective effect and when it is used in combination with sevoflurane, the latter is likely to completely deprive of the cardioprotective properties, by lowering the level of p-GSK-3^ below the reference values, which may be associated with the antioxidant properties of propofol. Evidently, further investigation should be continued to form ischemia/reperfusion groups when these anesthetics are co-administered. Key words: anesthetic preconditioning, sevorane, glycogen synthase kinase-3/3, Western blotting.</p></trans-abstract></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Takahata O., Ichihara K., Ogawa H.Acta Anaesthesiol. Scand.</mixed-citation><mixed-citation xml:lang="en">Takahata O., Ichihara K., Ogawa H.Acta Anaesthesiol. Scand.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Warltier D.C., Pagel P.S., Kersten J.R.Approaches to the prevention of perioperative myocardial ischemia.Anesthesiology.2000; 92 (1): 253— 259.</mixed-citation><mixed-citation xml:lang="en">Warltier D.C., Pagel P.S., Kersten J.R.Approaches to the prevention of perioperative myocardial ischemia.Anesthesiology.2000; 92 (1): 253— 259.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Schlack W., Hollmann M., Stunneck J., Thamer V.Effect of halothane on myocardial reoxygenation injury in the isolated rat heart.Br. J. Anaesth.1996; 76 (6): 860—867.</mixed-citation><mixed-citation xml:lang="en">Schlack W., Hollmann M., Stunneck J., Thamer V.Effect of halothane on myocardial reoxygenation injury in the isolated rat heart.Br. J. Anaesth.1996; 76 (6): 860—867.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">De Hert S.G., Turani F., Mathur S., Stowe D.F.Cardioprotection with volatile anesthetics: mechanisms and clinical implications.Anesth. Analg.2005; 100 (6): 1584—1593.</mixed-citation><mixed-citation xml:lang="en">De Hert S.G., Turani F., Mathur S., Stowe D.F.Cardioprotection with volatile anesthetics: mechanisms and clinical implications.Anesth. Analg.2005; 100 (6): 1584—1593.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cason BA., Gamperl A.K., Slocum R.E., Hickey R.F.Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocar-dial infarct size in rabbits.Anesthesiology.1997; 87 (5): 1182—1190.</mixed-citation><mixed-citation xml:lang="en">Cason BA., Gamperl A.K., Slocum R.E., Hickey R.F.Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocar-dial infarct size in rabbits.Anesthesiology.1997; 87 (5): 1182—1190.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tomai F., De Paulis R., Penta de Peppo A., Colagrande L., Caprara E., Polisca P., De Matteis G., Ghini A.S., Forlani S., Colella D., Chiariello L.Beneficial impact of isoflurane during coronary bypass surgery on tro-ponin I release.G. Ital. Cardiol.1999; 29 (9): 1007—1014.</mixed-citation><mixed-citation xml:lang="en">Tomai F., De Paulis R., Penta de Peppo A., Colagrande L., Caprara E., Polisca P., De Matteis G., Ghini A.S., Forlani S., Colella D., Chiariello L.Beneficial impact of isoflurane during coronary bypass surgery on tro-ponin I release.G. Ital. Cardiol.1999; 29 (9): 1007—1014.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">De Hert S., Vlasselaers D., Barbe R., Ory J.P., Dekegel D., Donnadonni R., Demeere J.L., Mulier J., Wouters P.A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery.Anaesthesia.2009; 64 (9): 953—960.</mixed-citation><mixed-citation xml:lang="en">De Hert S., Vlasselaers D., Barbe R., Ory J.P., Dekegel D., Donnadonni R., Demeere J.L., Mulier J., Wouters P.A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery.Anaesthesia.2009; 64 (9): 953—960.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">De Hert S.G., Longrois D., Yang H., Fleisher LA.Does the use of a volatile anesthetic regimen attenuate the incidence of cardiac events after vascular surgery?Acta Anaesthesiol. Belg.2008; 59 (1): 19—25.</mixed-citation><mixed-citation xml:lang="en">De Hert S.G., Longrois D., Yang H., Fleisher LA.Does the use of a volatile anesthetic regimen attenuate the incidence of cardiac events after vascular surgery?Acta Anaesthesiol. Belg.2008; 59 (1): 19—25.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">ЛихванцевВ.В., МорозВ.В., ГребенниковО.А., ГороховатскийЮ.И., ЗаржецкийЮ.В., ТимошинС.С., ЛевиковД.И., ШайбаковаВЛ.Ише-мическое и фармакологическое прекондиционирование.Общая реаниматология.2011; 7 (6): 59 &amp;#8212; 65.</mixed-citation><mixed-citation xml:lang="en">ЛихванцевВ.В., МорозВ.В., ГребенниковО.А., ГороховатскийЮ.И., ЗаржецкийЮ.В., ТимошинС.С., ЛевиковД.И., ШайбаковаВЛ.Ише-мическое и фармакологическое прекондиционирование.Общая реаниматология.2011; 7 (6): 59 &amp;#8212; 65.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Лихванцев В.В., Мороз В.В., Гребенников О.А., Гороховатский Ю.И., Заржецкий Ю.В., Тимошин С.С., Левиков Д.И., Шайбакова В.Л.Ише-мическое и фармакологическое прекондиционирование.Общаяреаниматология.2012; 8 (1): 61—66.</mixed-citation><mixed-citation xml:lang="en">Лихванцев В.В., Мороз В.В., Гребенников О.А., Гороховатский Ю.И., Заржецкий Ю.В., Тимошин С.С., Левиков Д.И., Шайбакова В.Л.Ише-мическое и фармакологическое прекондиционирование.Общаяреаниматология.2012; 8 (1): 61—66.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cleveland J.CJr., Meldrum D.R., Cain B.S., Banerjee A., Harken A.H.Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium.Circulation.1997; 96 (1): 29—32.</mixed-citation><mixed-citation xml:lang="en">Cleveland J.CJr., Meldrum D.R., Cain B.S., Banerjee A., Harken A.H.Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium.Circulation.1997; 96 (1): 29—32.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., Kiowski W., Amann F.W., Gruber D., Harris S., Burger W.Sulfonylureas and ischaemic preconditioning.Eur. Heart J.1999; 20 (6): 439—446.</mixed-citation><mixed-citation xml:lang="en">Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., Kiowski W., Amann F.W., Gruber D., Harris S., Burger W.Sulfonylureas and ischaemic preconditioning.Eur. Heart J.1999; 20 (6): 439—446.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Molojavyi A., Preckel B., Comfre T., Mullenheim J., Thamer V., Schlack W.Effects of ketamine and its isomers on ischemic preconditioning in the isolated rat heart.Anesthesiology.2001; 94 (4): 623—629.</mixed-citation><mixed-citation xml:lang="en">Molojavyi A., Preckel B., Comfre T., Mullenheim J., Thamer V., Schlack W.Effects of ketamine and its isomers on ischemic preconditioning in the isolated rat heart.Anesthesiology.2001; 94 (4): 623—629.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mullenheim J., Frassdorf J., Preckel B., Thamer V., Schlack W.Ketamine, but not S(+)-ketamine, blocks ischemic preconditioning in rabbit heartsin vivo. Anesthesiology.2001; 94 (4): 630—636.</mixed-citation><mixed-citation xml:lang="en">Mullenheim J., Frassdorf J., Preckel B., Thamer V., Schlack W.Ketamine, but not S(+)-ketamine, blocks ischemic preconditioning in rabbit heartsin vivo. Anesthesiology.2001; 94 (4): 630—636.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mullenheim J., Rulands R., Wietschorke T., Frassdorf J., Preckel B., Schlack W.Late preconditioning is blocked by racemic ketamine, but not by S(+)-Ketamine.Anesth. Analg.2001; 93 (2): 265—270.</mixed-citation><mixed-citation xml:lang="en">Mullenheim J., Rulands R., Wietschorke T., Frassdorf J., Preckel B., Schlack W.Late preconditioning is blocked by racemic ketamine, but not by S(+)-Ketamine.Anesth. Analg.2001; 93 (2): 265—270.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kozlowski R.Z., Ashford M.LJ.Barbiturates inhibit ATP-K+ channels and voltage-activated currents in CRI-G1 insulin-secreting cells.Br. J. Pharmacol1991; 103 (4): 2021—2029.</mixed-citation><mixed-citation xml:lang="en">Kozlowski R.Z., Ashford M.LJ.Barbiturates inhibit ATP-K+ channels and voltage-activated currents in CRI-G1 insulin-secreting cells.Br. J. Pharmacol1991; 103 (4): 2021—2029.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tsutsumi Y., Oshita S., Kitahata H., Kuroda Y., Kawano T., Nakaya Y.Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes.Anesthesiology.2000; 92 (4): 1154—1159.</mixed-citation><mixed-citation xml:lang="en">Tsutsumi Y., Oshita S., Kitahata H., Kuroda Y., Kawano T., Nakaya Y.Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes.Anesthesiology.2000; 92 (4): 1154—1159.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mullenheim J., Molojavyi A., Preckel B., Thamer V., Schlack W.Thiopentone does not block ischemic preconditioning in the isolated rat heart.Can. J. Anesth.2001; 48 (8): 784—789.</mixed-citation><mixed-citation xml:lang="en">Mullenheim J., Molojavyi A., Preckel B., Thamer V., Schlack W.Thiopentone does not block ischemic preconditioning in the isolated rat heart.Can. J. Anesth.2001; 48 (8): 784—789.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Murphy P.G., Myers D.S., Davies M.J., Webster N.R., Jones J.G.The antioxidant potential of propofol (2,6—diisopropylphenol).Br. J. Anaesth.1992; 68 (6): 613—618.</mixed-citation><mixed-citation xml:lang="en">Murphy P.G., Myers D.S., Davies M.J., Webster N.R., Jones J.G.The antioxidant potential of propofol (2,6—diisopropylphenol).Br. J. Anaesth.1992; 68 (6): 613—618.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kokita N., Hara A.Propofol attenuates hydrogen peroxide-induced mechanical and metabolic derangements in the isolated rat heart.Anesthesiology.1996; 84 (1): 117—127.</mixed-citation><mixed-citation xml:lang="en">Kokita N., Hara A.Propofol attenuates hydrogen peroxide-induced mechanical and metabolic derangements in the isolated rat heart.Anesthesiology.1996; 84 (1): 117—127.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sztark F., Ichas F., Ouhabi R., Dabadie P., MazatJP.Effects of the anaesthetic propofol on the calcium-induced permeability transition of rat heart mitochondria: direct pore inhibition and shift of the gating potential.FEBS Letters.1995; 368 (1): 101—104.</mixed-citation><mixed-citation xml:lang="en">Sztark F., Ichas F., Ouhabi R., Dabadie P., MazatJP.Effects of the anaesthetic propofol on the calcium-induced permeability transition of rat heart mitochondria: direct pore inhibition and shift of the gating potential.FEBS Letters.1995; 368 (1): 101—104.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J.M., Jang Y.H., Kim J.Morphine and remifentanil-induced cardio-protection: its experimental and clinical outcomes.Korean J. Anesthesiol.2011; 61 (5): 358—366.</mixed-citation><mixed-citation xml:lang="en">Kim J.M., Jang Y.H., Kim J.Morphine and remifentanil-induced cardio-protection: its experimental and clinical outcomes.Korean J. Anesthesiol.2011; 61 (5): 358—366.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">EbelD., Schlack W., Comfrne T., PreckelB., Thamer V.Effect of propofol on reperfusion injury after regional ischaemia in the isolated rat heart.Br. J. Anaesth.1999; 83 (6): 903—908.</mixed-citation><mixed-citation xml:lang="en">EbelD., Schlack W., Comfrne T., PreckelB., Thamer V.Effect of propofol on reperfusion injury after regional ischaemia in the isolated rat heart.Br. J. Anaesth.1999; 83 (6): 903—908.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Xia Z., Huang Z., Ansley D.M.Large-dose propofol during cardiopul-monary bypass decreases biochemical markers of myocardial injury in coronary surgery patients: acomparison with isoflurane.Anesth. Analg.2006; 103 (3): 527—532.</mixed-citation><mixed-citation xml:lang="en">Xia Z., Huang Z., Ansley D.M.Large-dose propofol during cardiopul-monary bypass decreases biochemical markers of myocardial injury in coronary surgery patients: acomparison with isoflurane.Anesth. Analg.2006; 103 (3): 527—532.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">ШевченкоЮЛ., ГороховатскийЮ.И., АзизоваО.А., ГудымовичВ.Г.Севофлуран в кардиохирургии.Кардиология и сердечно-сосудистая хирургия.2009; 2 (2): 58—65.</mixed-citation><mixed-citation xml:lang="en">ШевченкоЮЛ., ГороховатскийЮ.И., АзизоваО.А., ГудымовичВ.Г.Севофлуран в кардиохирургии.Кардиология и сердечно-сосудистая хирургия.2009; 2 (2): 58—65.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Корпачев В.Г., Лысенков С.П., Тель Л.З.Моделирование клинической смерти и постреанимационной болезни у крыс.Патол. физиология и экперим. терапия.1982; 3: 78—80.</mixed-citation><mixed-citation xml:lang="en">Корпачев В.Г., Лысенков С.П., Тель Л.З.Моделирование клинической смерти и постреанимационной болезни у крыс.Патол. физиология и экперим. терапия.1982; 3: 78—80.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Лихванцев В.В., Гребенчиков ОА., Борисов К.Ю.Механизмы фармакологического прекондиционирования мозга и сравнительная эффективность препаратов &amp;#8212; ингибиторов гликоген-синтетазы-кина-зы &amp;#8212; 3-бета прямого и непрямого действия.Общая реаниматология.2012; 8 (6): 37—43.</mixed-citation><mixed-citation xml:lang="en">Лихванцев В.В., Гребенчиков ОА., Борисов К.Ю.Механизмы фармакологического прекондиционирования мозга и сравнительная эффективность препаратов &amp;#8212; ингибиторов гликоген-синтетазы-кина-зы &amp;#8212; 3-бета прямого и непрямого действия.Общая реаниматология.2012; 8 (6): 37—43.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Гребенчиков О.А., Мурачев А.С., Левиков Д.И., Селиванов Д.Д., Лих-ванцев В.В.Ингаляцоинная индукция на основе севофлурана у пожилых больных высокого риска в некардиальной хирургии.Общаяреаниматология.2011; 7 (3): 59—62.</mixed-citation><mixed-citation xml:lang="en">Гребенчиков О.А., Мурачев А.С., Левиков Д.И., Селиванов Д.Д., Лих-ванцев В.В.Ингаляцоинная индукция на основе севофлурана у пожилых больных высокого риска в некардиальной хирургии.Общаяреаниматология.2011; 7 (3): 59—62.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Baines C.P., Pass J.M., Ping P.Protein kinases and kinase-modulated effectors in the late phase of ischemic preconditioning.Basic. Res. Cardiol.2001; 96 (3): 207—218.</mixed-citation><mixed-citation xml:lang="en">Baines C.P., Pass J.M., Ping P.Protein kinases and kinase-modulated effectors in the late phase of ischemic preconditioning.Basic. Res. Cardiol.2001; 96 (3): 207—218.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Strasser R.H., Braun-Dullaeus R., Walendzik H., Marquetant R.Alpha 1-receptor-independent activation of protein kinase C in acute myocar-dial ischemia. Mechanisms for sensitization of the adenylyl cyclase system.Circ. Res.1992; 70 (6): 1304—1312.</mixed-citation><mixed-citation xml:lang="en">Strasser R.H., Braun-Dullaeus R., Walendzik H., Marquetant R.Alpha 1-receptor-independent activation of protein kinase C in acute myocar-dial ischemia. Mechanisms for sensitization of the adenylyl cyclase system.Circ. Res.1992; 70 (6): 1304—1312.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kawamura S., Yoshida K., Miura T., Mizukami Y., Matsuzaki M.Ischemic preconditioning translocates PKC-delta and -epsilon, which mediate functional protection in isolated rat heart.Am. J. Physiol.1998; 275 (6 Pt 2): H2266—H2271.</mixed-citation><mixed-citation xml:lang="en">Kawamura S., Yoshida K., Miura T., Mizukami Y., Matsuzaki M.Ischemic preconditioning translocates PKC-delta and -epsilon, which mediate functional protection in isolated rat heart.Am. J. Physiol.1998; 275 (6 Pt 2): H2266—H2271.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Billman G.E.Role of ATP sensitive potassium channel in extracellular potassium accumulation and cardiac arrhythmias during myocardial ischaemia.Cardiovasc. Res.1994; 28 (6): 762—769.</mixed-citation><mixed-citation xml:lang="en">Billman G.E.Role of ATP sensitive potassium channel in extracellular potassium accumulation and cardiac arrhythmias during myocardial ischaemia.Cardiovasc. Res.1994; 28 (6): 762—769.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Murata M., Akao M., O&amp;#8217;Rourke B., Marban E.Mitochondrial ATP-sensi-tive potassium channels attenuate matrix Ca2+overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection.Circ. Res.2001; 89 (10): 891—898.</mixed-citation><mixed-citation xml:lang="en">Murata M., Akao M., O&amp;#8217;Rourke B., Marban E.Mitochondrial ATP-sensi-tive potassium channels attenuate matrix Ca2+overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection.Circ. Res.2001; 89 (10): 891—898.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L., Cherednichenko G., Hernandez L., Halow J., Camacho S.A., Figueredo V., Schaefer S.Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: role of K(ATP) channels.Am. J. Physiol. Heart Circ. Physiol.2001; 280 (5): H2321—H2328.</mixed-citation><mixed-citation xml:lang="en">Wang L., Cherednichenko G., Hernandez L., Halow J., Camacho S.A., Figueredo V., Schaefer S.Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: role of K(ATP) channels.Am. J. Physiol. Heart Circ. Physiol.2001; 280 (5): H2321—H2328.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zaugg M., Lucchinetti E., Spahn D.R., Pasch T., Schaub M.C.Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways.Anesthesiology.2002; 97 (1): 4—14.</mixed-citation><mixed-citation xml:lang="en">Zaugg M., Lucchinetti E., Spahn D.R., Pasch T., Schaub M.C.Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways.Anesthesiology.2002; 97 (1): 4—14.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">de Ruijter W., Musters RJ., Boer C., Stienen GJ., SimonidesW.S.,de Lange J.J.The cardioprotective effect of sevoflurane depends on protein kinase C activation, opening of mitochondrial K+ATPchannels, and the production of reactive oxygen species.Anesth. Analg.2003; 97 (5): 1370—1376.</mixed-citation><mixed-citation xml:lang="en">de Ruijter W., Musters RJ., Boer C., Stienen GJ., SimonidesW.S.,de Lange J.J.The cardioprotective effect of sevoflurane depends on protein kinase C activation, opening of mitochondrial K+ATPchannels, and the production of reactive oxygen species.Anesth. Analg.2003; 97 (5): 1370—1376.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Murry C.E., Richard V.J., Jennings R.B., Reimer K.A.Preconditioning with ischemia: is the protective effect mediated by free radical induced myocardial stunning?Circulation.1988; 78 (2): 77—84.</mixed-citation><mixed-citation xml:lang="en">Murry C.E., Richard V.J., Jennings R.B., Reimer K.A.Preconditioning with ischemia: is the protective effect mediated by free radical induced myocardial stunning?Circulation.1988; 78 (2): 77—84.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Chen W., Gabel S., Steenbergen C., Murphy E.A redox-based mechanism for cardioprotection induced by ischemic preconditioning in perfused rat.Heart Circ. Res.1995; 77 (2): 424—429.</mixed-citation><mixed-citation xml:lang="en">Chen W., Gabel S., Steenbergen C., Murphy E.A redox-based mechanism for cardioprotection induced by ischemic preconditioning in perfused rat.Heart Circ. Res.1995; 77 (2): 424—429.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Forbes R.A., Steenbergen C., Murphy E.Diazoxide-induced cardiopro-tection requires signaling through a redox-sensitive mechanism.Circ. Res.2001; 88 (8): 802—809.</mixed-citation><mixed-citation xml:lang="en">Forbes R.A., Steenbergen C., Murphy E.Diazoxide-induced cardiopro-tection requires signaling through a redox-sensitive mechanism.Circ. Res.2001; 88 (8): 802—809.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Griffiths E.J., Halestrap A.P.Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion.Biochem. J.1995; 307 (1): 93—98.</mixed-citation><mixed-citation xml:lang="en">Griffiths E.J., Halestrap A.P.Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion.Biochem. J.1995; 307 (1): 93—98.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., Ziman B.D., Wang S., Ytrehus K., Antos C.L., Olson E.N., Sollott SJ.Glycogen synthase kinase-3b mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore.J. Clin. Invest.2004; 113 (11): 1535—1549.</mixed-citation><mixed-citation xml:lang="en">Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., Ziman B.D., Wang S., Ytrehus K., Antos C.L., Olson E.N., Sollott SJ.Glycogen synthase kinase-3b mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore.J. Clin. Invest.2004; 113 (11): 1535—1549.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Sato T., Sasaki N., O&amp;#8217;Rourke B., Marban E.Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: a key step in ischemic preconditioning?Circulation.2000; 102 (7): 800—805.</mixed-citation><mixed-citation xml:lang="en">Sato T., Sasaki N., O&amp;#8217;Rourke B., Marban E.Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: a key step in ischemic preconditioning?Circulation.2000; 102 (7): 800—805.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Tong H., Imahashi K., Steenbergen C., Murphy E.Phosphorylation of glycogen synthase kinase-3b during preconditioning through a phos-phatidylinositol-3—kinase-dependent pathway is cardioprotective.Circ. Res.2002; 90 (4): 377—379.</mixed-citation><mixed-citation xml:lang="en">Tong H., Imahashi K., Steenbergen C., Murphy E.Phosphorylation of glycogen synthase kinase-3b during preconditioning through a phos-phatidylinositol-3—kinase-dependent pathway is cardioprotective.Circ. Res.2002; 90 (4): 377—379.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Wu Q.L., Shen T., Shao L.L., Ma H., Wang J.K.Ischemic postcondition-ing mediates cardioprotection via PI3K/GSK-3b/E-catenin signaling pathway in ischemic rat myocardium.Shock.2012; 38 (2): 165—169.</mixed-citation><mixed-citation xml:lang="en">Wu Q.L., Shen T., Shao L.L., Ma H., Wang J.K.Ischemic postcondition-ing mediates cardioprotection via PI3K/GSK-3b/E-catenin signaling pathway in ischemic rat myocardium.Shock.2012; 38 (2): 165—169.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Onishi A., Miyamae M., Kaneda K., Kotani J., Figueredo V.M.Direct evidence for inhibition of mitochondrial permeability transition pore opening by sevoflurane preconditioning in cardiomyocytes: comparison with cyclosporine A.Eur. J. Pharmacol.2012; 675 (1—3): 40—46.</mixed-citation><mixed-citation xml:lang="en">Onishi A., Miyamae M., Kaneda K., Kotani J., Figueredo V.M.Direct evidence for inhibition of mitochondrial permeability transition pore opening by sevoflurane preconditioning in cardiomyocytes: comparison with cyclosporine A.Eur. J. Pharmacol.2012; 675 (1—3): 40—46.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Green D.R., ReedJ.C.Mitochondria and apoptosis.Science.1998; 281 (5381): 1309—1312.</mixed-citation><mixed-citation xml:lang="en">Green D.R., ReedJ.C.Mitochondria and apoptosis.Science.1998; 281 (5381): 1309—1312.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Bernardi P.The mitochondrial permeability transition pore: a mystery solved?Front Physiol.2013; 4: 95.</mixed-citation><mixed-citation xml:lang="en">Bernardi P.The mitochondrial permeability transition pore: a mystery solved?Front Physiol.2013; 4: 95.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Siemen D., Ziemer M.What is the nature of the mitochondrial permeability transition pore and what is it not?IUBMBLife.2013; 65 (3): 255—262.</mixed-citation><mixed-citation xml:lang="en">Siemen D., Ziemer M.What is the nature of the mitochondrial permeability transition pore and what is it not?IUBMBLife.2013; 65 (3): 255—262.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
